Noxopharm Announces novel mRNA “vaccine enhancer” product
- Noxopharm (NOX) is developing a new mRNA “vaccine enhancer” product to improve the effectiveness of vaccines and reduce inflammation
- The company says it has selected a lead candidate for further development, and the product — dubbed SOF-VAC — will be part of its Sofra preclinical platform
- NOX says SOF-VAC is the smallest known molecule of its type to have demonstrated “strong activity” against inflammation
- The company is developing the product in partnership with the Hudson Institute of Medical Research
- Shares in the company are up 3.16 per cent to 9.8 cents at midday AEDT
